

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appligant:

Bernd DORKEN et al.

Title:

NOVEL CD19xCD3 SPECIFIC POLYPEPTIDES

AND USES THEREOF.

Appl. No.:

09/673,735

Filing Date:

December 27, 2000

Examiner:

Unassigned

Art Unit:

Unassigned


## **INFORMATION DISCLOSURE STATEMENT**


Commissioner for Patents Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.





Documents A1 - A10 came to Applicants' attention during the prosecution of the corresponding International application. A copy of the International Search Report is attached setting forth the portion of each document considered relevant by the examiner.

Documents A11 - A16 were mentioned in a response, dated May 16, 2000, to a Written Opinion issued by the European Patent Office acting as the IPEA on February 17, 2000, concerning the International application.

English translations of Documents A1 and A12 are not readily available; however, the absence of such translations does not relieve the PTO from its duty to consider the submitted documents (37 CFR §1.98 and MPEP§603). An English language summary is included with Document A12.

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

Respectfully submitted,

Date 27 Accember 2000

**FOLEY & LARDNER** Washington Harbour 3000 K Street, N.W., Suite 500 Washington, D.C. 20007-5109

Telephone: (202) 672-5404

Facsimile:

(202) 672-5399

Stephen A. Bent Attorney for Applicant Registration No. 29,768

)

<u>Page 1 of 2</u>

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE			ATTY, DOCKET NO.		SERIAL NO.			
(MODIFIED)		PATENT AND TRADEMARK OFFICE		=	028622/0102 APPLICANT		09/673,735			
INF	ORMATI	ON DISCLOSURE	CITATION			rnd DORKE	N et al.			
					FILING DATE		GROUP ART UNIT			
(Use several sheets if necessary)					December 27, 2000		Unassigned			
•			U.S. PAT	EN.	T DOCUMENTS		<u> </u>			
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	··NAME CLASS		SUB- CLASS				
-									-	
	•		FOREIGN P	ATE	ENT DOCUMENTS					
	REF	DOCUMENT	DATE		COUNTRY	CLASS	SUB-	TRANS	LATION	
		NUMBER				00.00	CLASS	YES	NO	
	A1	195 31 348			Republic of Germany				×	
	A2 -			Euro						
	A3	91/09968		VIP(					-	
	A4_	95/11922		VIP(						
	A5 (	96/36360	11/21/96 V	VIP(	<u> </u>					
		OTHER DOCU	MENTS (Including	g Aı	ıthor, Title, Date, Pert	inent Pages,	Etc.)			
	H. Bohlen et al., "TREATMENT OF EB-VIRUS INDUCED B-CELL LCL IN SCID-HU MICE USING CD3XCD19 BISPECIFIC AND CD28 ANTIBODIES.", Proceedings of the American Association for Cancer Research, vol. 35, March, 1994, pg. 510, XP-002076122, abstract.									
	A7	Jan De Jonge et al., "Bispecific antibody treatment of murine B cell lymphoma.", Cancer Immunology Immunotherapy, vol. 45, No. 3/4, pp. 162-165, XP-002076120, Springer-Verlag, 1997								
	A8	Sergey M. Kipriyanov et al., "BISPECIFIC CD3 X CD19 DIABODY FOR T-CELL-MEDIATED LYSIS OF MALIGNANT HUMAN B CELLS.", International Journal of Cancer, vol. 77, August 31, 1998, pp. 763-772, XP-002115487, Wiley-Liss, Inc., 1998								
	A9 ~	P. Kufer et al., "Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer.", Cancer Immunology Immunotherapy, vol. 45, No. 3/4, pp. 193-197, XP-002076121, Springer-Verlag, 1997								
	A10	Anja Schroder et al., "A RECOMBINANT BISPECIFIC SINGLE CHAIN ANTIBODY CD19XCD3 INDUCED RAPID B CELL LYMPHOMA-DIRECTED CYTOTOXICITY OF UNSTIMULATED HUMAN T CELLS.", 40 <sup>th</sup> Annual Meeting Of The American Society Of Hematology Miami Beach, Florida, December 4-8, 1998, XP-002115457, abstract.								
EXAMINER				DATE CONSIDERED						
				- 4.				IDED 664	0. D.:-:-	
line	through				er or not citation is not considered. In					

Page 2 of 2

Form PTO-1449	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.				
(MODIFIED)	PATENT AND TRADEMARK OFFICE	028622/0102	09/673,735				
		APPLICANT					
INFORMATION DISCLOSURE CITATION		Bernd DORKEN et al.					
		FILING DATE	GROUP ART UNIT				
(Use	several sheets if necessary)	December 27, 2000	Unassigned				
	OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent Pages,	Etc.)				
A11	"National Cancer Institute Sponsored Study of Classifications of Non-Hodgkin's Lymphomas, Summary and Description of a Working Formulation for Clinical Usage.", Cancer, vol. 49, pp. 2112-2135, 1982, (Exhibit 1)						
A12		ssifikation der malignen Lymphome.", Deutsches Arzteblatt, vol. 96, pp. uding English language summary, (Exhibit 2)					
A13	Parveen Kumar et al., 3 <sup>rd</sup> Edition, Clinical Medicine, pp. 369-370, Bailliere Tindall, (Exhibit 3)						
A14	Jan De Jonge et al., "PRODUCTION AND CHARACTERIZATION OF BISPECIFIC SINGLE-CHAIN ANTIBODY FRAGMENTS.", Molecular Immunology, vol. 32, No. 17/18, pp. 1405-1412, 1995, (Exhibit 4)						
A15	Fv (Anti-CD3 X Anti-Idiotype) Induces Lor	Jan De Jonge et al., "In Vivo Retargeting of T Cell Effector Function by Recombinant Bispecific Single Chain Fv (Anti-CD3 X Anti-Idiotype) Induces Long-Term Survival in the Murine BCL1 Lymphoma Model1.", The Journal of Immunology, vol. 161, pp. 1454-1461, 1998, (Exhibit 5)					
A16	Matthias Mack et al., "Biologic Properties of a Bispecific Single-Chain Antibody Directed Against 17-1A (EpCAM) and CD3.", Proceedings of the National Academy of Science, vol. 92, pp. 7021-7025, 1995, (Exhibit 6)						
#							
EXAMINER		DATE CONSIDERED					
line throug	R: Initial if citation considered, wheth the citation if not in conformance and ation to applicant.	er or not citation is in conformation not considered. Include any c	ance with MPEP 609; Draw opy of this form with next				